Epirus Biopharmaceuticals Company Profile (NASDAQ:CRXX)

About Epirus Biopharmaceuticals (NASDAQ:CRXX)

Epirus Biopharmaceuticals logoEPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company's products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.

Industry, Sector and Symbol:
P/E:
  • Trailing P/E Ratio:
  • P/E Growth:
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: -2,025.65%
  • Return on Equity: -208.66%
  • Return on Assets: -97.67%
 

Frequently Asked Questions for Epirus Biopharmaceuticals (NASDAQ:CRXX)

What is Epirus Biopharmaceuticals' stock symbol?

Epirus Biopharmaceuticals trades on the NASDAQ under the ticker symbol "CRXX."

Who are some of Epirus Biopharmaceuticals' key competitors?

Who are Epirus Biopharmaceuticals' key executives?

Epirus Biopharmaceuticals' management team includes the folowing people:

  • Robert Ticktin, Senior Vice President, General Counsel, Secretary
  • Vincent E. Aurentz, Chief Business Officer

How do I buy Epirus Biopharmaceuticals stock?

Shares of Epirus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.


MarketBeat Community Rating for Epirus Biopharmaceuticals (NASDAQ CRXX)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  29 (Vote Outperform)
Underperform Votes:  20 (Vote Underperform)
Total Votes:  49
MarketBeat's community ratings are surveys of what our community members think about Epirus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Epirus Biopharmaceuticals (NASDAQ:CRXX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Epirus Biopharmaceuticals (NASDAQ:CRXX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Epirus Biopharmaceuticals (NASDAQ:CRXX)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Epirus Biopharmaceuticals (NASDAQ:CRXX)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Epirus Biopharmaceuticals (NASDAQ:CRXX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Epirus Biopharmaceuticals (NASDAQ:CRXX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Epirus Biopharmaceuticals (NASDAQ:CRXX)
Latest Headlines for Epirus Biopharmaceuticals (NASDAQ:CRXX)
Source:
No headlines for this company have been tracked by MarketBeat.com

Social

Chart

Epirus Biopharmaceuticals (CRXX) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff